Current developments of targeting the p53 signaling pathway for cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The p53 tumor suppressor is frequently altered in cancers, either through mutation/deletion or pathway disruption.
• Targeting the p53 pathway is a high-priority goal for cancer drug development due to its critical role.
• Despite extensive research, developing effective p53-targeting therapeutics has proven exceptionally difficult.

Purpose of the Study:

• To review past and current strategies for developing p53-based gene and targeted therapies for cancer.
• To examine emerging approaches utilizing p53 immunogenicity for cancer immunotherapy.
• To discuss the challenges and future directions in targeting the p53 pathway.

Main Methods:

• Literature review of p53-based cancer therapies.
• Analysis of gene therapy, targeted therapy, and immunotherapy approaches.
• Discussion of challenges and future research avenues.

Main Results:

• Review covers historical and contemporary p53-targeting strategies.
• Highlights the potential of p53-based immunotherapy.
• Identifies significant hurdles in clinical translation.

Conclusions:

• Developing effective p53-targeting cancer therapies remains a significant challenge.
• Novel approaches, including immunotherapy, show promise.
• Further research is needed to overcome obstacles and advance p53-based treatments.